PLx Pharma Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $2.53 million
- Book Value:
- Revenue TTM:
- $4.54 million
- Operating Margin TTM:
- Gross Profit TTM:
- $3.40 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
PLx Pharma Inc had its IPO on 2014-03-13 under the ticker symbol PLXP.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. PLx Pharma Inc has a staff strength of 16 employees.
Shares of PLx Pharma Inc opened at $0.01 at the start of the last trading session i.e. 2023-05-28.
The stocks traded within a range of $0 - $0.01, and closed at $0.01.
This is a -9.09% slip from the previous day's closing price.
A total volume of 724,782 shares were traded at the close of the day’s session.
In the last one week, shares of PLx Pharma Inc have slipped by -47.37%.
PLx Pharma Inc's Key Ratios
PLx Pharma Inc has a market cap of $2.53 million, indicating a price to book ratio of 0.5818 and a price to sales ratio of 1.2902.
In the last 12-months PLx Pharma Inc’s revenue was $4.54 million with a gross profit of $3.40 million and an EBITDA of $-64305000. The EBITDA ratio measures PLx Pharma Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, PLx Pharma Inc’s operating margin was -1417.8% while its return on assets stood at -64.39% with a return of equity of -75.18%.
In Q3, PLx Pharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 94.2%.
PLx Pharma Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.39 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.11. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into PLx Pharma Inc’s profitability.
PLx Pharma Inc stock is trading at a EV to sales ratio of 1.2071 and a EV to EBITDA ratio of -0.0854. Its price to sales ratio in the trailing 12-months stood at 1.2902.
PLx Pharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $33.22 million
- Total Liabilities
- $6.31 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
PLx Pharma Inc ended 2023 with $33.22 million in total assets and $0 in total liabilities. Its intangible assets were valued at $33.22 million while shareholder equity stood at $26.20 million.
PLx Pharma Inc ended 2023 with $0 in deferred long-term liabilities, $6.31 million in other current liabilities, 29000.00 in common stock, $-179414000.00 in retained earnings and $2.06 million in goodwill. Its cash balance stood at $25.83 million and cash and short-term investments were $25.83 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
PLx Pharma Inc’s total current assets stands at $30.22 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $139000.00 compared to accounts payable of $5.07 million and inventory worth $3.18 million.
In 2023, PLx Pharma Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, PLx Pharma Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
PLx Pharma Inc stock is currently trading at $0.01 per share. It touched a 52-week high of $3.08 and a 52-week low of $3.08. Analysts tracking the stock have a 12-month average target price of $11.
Its 50-day moving average was $0.06 and 200-day moving average was $0.35 The short ratio stood at 0.83 indicating a short percent outstanding of 0%.
Around 1539.1% of the company’s stock are held by insiders while 2325.5% are held by institutions.
Frequently Asked Questions About PLx Pharma Inc
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company’s lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules. Its product pipeline also includes PL1200 Ibuprofen 200 mg; and PL1100 Ibuprofen 400 mg, which are in Phase I clinical stage for pain, inflammation, and fever. The company sells its products through drugstores, mass merchandisers, grocery stores, and e-commerce channels. PLx Pharma Inc. was incorporated in 2002 and is headquartered in Sparta, New Jersey. On April 13, 2023, PLx Pharma Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.